secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2024-01-24T23:59:59+00:00
Accession:  0001628280-24-002009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q4 adj EPS $1.19, base organic +11%; FY24 guide $4.50-$4.70
------------------------------------------------------------------

- Q4 reported sales $10.241B (+1.5%); organic base business growth +11.0% excluding COVID tests.
- GAAP diluted EPS $0.91; adjusted diluted EPS $1.19. Full-year 2023 adjusted EPS $4.44.
- FY2024 guidance: GAAP EPS $3.20-$3.40, adjusted EPS $4.50-$4.70; organic sales growth 8-10% ex-COVID.
- Medical Devices sales +17.5% reported; FreeStyle Libre revenue $1.4B (+23.8% organic).
- Nutrition sales +12.2% reported, +13.9% organic; U.S. infant formula regained market-leading position.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/0001628280-24-002009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/abt-20240124.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-002009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer